Drug resistance analysis on the drug resistance of Streptococcus agalactiae isolated from female urogenital tract

doi:10.3969/j.issn.1673-8640.2015.01.004

Abstract

Abstract:

Objective To analyze retrospectively the drug resistance of Streptococcus agalactiae isolated from female urogenital tract, to understand the drug resistance tendency change of commonly-used antibiotics, and to guide the rational use of antibiotics in clinical application. Methods The routine culture was performed for female urogenital tract specimens collected from January 2009 to December 2012, and the identification and drug sensitivity test were performed for Streptococcus agalactiae by VITEK32 automatic bacterium identification analyzer. The D-inhibition zone trial was tested for isolates which were drug-resistant to erythromycin and sensitive or intermediary to clindamycin. Results There was a statistical significance in age distribution among 569 specimens from Department of Gynecology and 192 specimens from Department of Obstetrics (P<0.01). Drug resistance rate was 0 to vancomycin and <3% to penicillin and linezolid. The drug resistance rate of nitrofurantoin was <0.5% from 2009 to 2011 and suddenly increased to 7.2% in 2012. The drug resistance rate of tetracycline exceeded 90%. Erythromycin, clindamycin and levofloxacin reflected high drug resistance rates and such an increasing tendency year by year. The positive rate of D-inhibition zone trial was 21.7%. Conclusions It is required to rationally use antibiotics in clinical application according to the drug sensitivity test results. Meanwhile, the drug resistance monitoring in clinical application should be strengthened.

Key words: Streptococcus agalactiae, Urogenital tract, Drug resistance

CLC Number:

R446.5

GAO Jing, LIU Xiaoyan.. Drug resistance analysis on the drug resistance of Streptococcus agalactiae isolated from female urogenital tract[J]. Laboratory Medicine, 2015, 30(1): 13-16.

Figures/Tables 2

References 12

[1]	叶应妩,王毓三,申子瑜.全国临床检验操作规程[M].3版.南京:东南大学出版社,2006:707.
[2]	Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing[S]. M100-S22,CLSI, 2012.
[3]	SJUNKARA B, BHEEMREDDV S, LORBER B, et al.Group B Streptococcus infections in non-pregnant adults:the role of immunosuppression[J].Int J Infect Dis, 2012,16(3):e182-e186.
[4]	CHURCH D, CARSON J, GREGSON D.Point prevalence study of antibiotic susceptibility of genital group B Streptococcus isolated from near-term pregnant women in Calgaru, Alberta[J]. Can J Infect Dis, 2012, 23(3):121-124.
[5]	郭素芳,张迎华,周敏,等.泌尿生殖道分离无乳链球菌药物敏感性分析[J].检验医学,2008,23(6):612-614.
[6]	SHEEN TR, JIMENEZ A, WANG NY, et al.Serine-rich repeat proteins and pili promote Streptococcus agalactiae colonization of the vaginal tract[J]. J Bacteriol, 2011, 193(24): 6834-6842.
[7]	曾宪玉,王辉,王玮蓁等.多重PCR/反向线点杂交检测B族溶血性链球菌耐药相关基因的研究[J].中华检验医学杂志,2007,30(4):419-423.
[8]	DE FRANCESCO MA, CARACCIOLO S, GARGIULO F, et al.Phenotypes, genotypes, serotypes and molecular epidemiology of erythromycin-resistant Streptococcus agalactiae in Italy[J]. Eur J Clin Microbiol Infect Dis, 2012, 31(8):1741-1747.
[9]	DRAMSI S, MORELLO E, POYART C, et al.Epidemiologically and clinically relevant Group B Streptococcus isolates do not bind collagen but display enhanced binding to human fibrinogen[J].Microbes Infect, 2012,14(12):1044-1048.
[10]	SHARMA P, LATA H, ARYA DK, et al.Role of pilus proteins in adherence and invasion of Streptococcus agalactiae to the lung and cervical epithelial cells[J]. J Biol Chem, 2013, 288(6): 4023-4034.
[11]	DE ZOYSA A, EDWARDS K, GHARBOA S, et al.Non-culture detection of Streptococcus agalactiae (Lancefield group B Streptococcus) in clinical samples by real-time PCR[J]. J Med Microbiol, 2012, 61(Pt 8):1086-1090.
[12]	American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised guidelinds for prevention of early-onset group B streptococcal(GBS)infection[J]. Pediatrics, 1997, 99(3): 489-496.

年龄(岁)	总例数	妇科			产科
年龄(岁)	总例数	例数	无乳链球菌(株)	检出率(%)	例数	无乳链球菌(株)	检出率(%)
≤20	703	650	13	2.00	53	1	1.90
21~40	21 624	13 728	388	2.83	7 896	189	2.39
41~60	3 757	3 686	152	4.12	71	2	2.82
≥61	553	553	16	2.89	0	0	0.00
合计	26 637	18 617	569	3.10	8 020	192	2.40

年龄(岁)	总例数	妇科			产科
年龄(岁)	总例数	例数	无乳链球菌(株)	检出率(%)	例数	无乳链球菌(株)	检出率(%)
≤20	703	650	13	2.00	53	1	1.90
21~40	21 624	13 728	388	2.83	7 896	189	2.39
41~60	3 757	3 686	152	4.12	71	2	2.82
≥61	553	553	16	2.89	0	0	0.00
合计	26 637	18 617	569	3.10	8 020	192	2.40

抗菌药物	2009年(75株)					2010年(183株)
抗菌药物	MIC50	MIC90	MIC范围		R(%)	MIC50	MIC90	MIC范围		R(%)
克林霉素	0.25	8.00	0.125	~8	33.3	0.25	8.00	0.125	~8	33.3
红霉素	0.50	8.00	0.125	~8	48.0	0.50	8.00	0.25	~8	49.7
左氧氟沙星	1.00	8.00	0.5	~8	20.0	1.00	8.00	1	~16	28.4
利奈唑胺	2.00	2.00	1	~16	1.3	2.00	2.00	1	~8	1.6
呋喃妥因	32.00	32.00	16	~64	0.0	32.00	32.00	32	~128	0.5
青霉素G	0.032	0.032	0.015	~16	2.7	0.032	0.032	0.015	~16	1.6
四环素	16.00	16.00	1	~32	92.0	16.00	16.00	1	~16	90.2
万古霉素	0.50	0.50	0.5	~32	0.0	0.50	0.50	0.5	~32	0.0
抗菌药物	2011年(238株)					2012年(264株)
抗菌药物	MIC50	MIC90	MIC范围		R(%)	MIC50	MIC90	MIC范围		R(%)
克林霉素	0.25	8.00	0.25	~8	33.2	0.25	8.00	0.125	~8	33.3
红霉素	0.50	8.00	0.25	~8	49.6	1.00	8.00	0.125	~16	56.5
左氧氟沙星	1.00	8.00	1	~8	30.3	1.00	8.00	1	~8	30.7
利奈唑胺	2.00	2.00	2	~2	0.0	2.00	2.00	0.5	~2	0.0
呋喃妥因	32.00	32.00	32	~128	0.4	32.00	64.00	16	~256	7.2
青霉素G	0.032	0.032	0.03	~16	0.4	0.032	0.032	0.03	~8	0.4
四环素	16.00	16.00	1	~16	90.3	16.00	16.00	1	~16	90.5
万古霉素	0.50	0.50	0.5	~2	0.0	0.50	0.50	0.5	~2	0.0

抗菌药物	2009年(75株)					2010年(183株)
抗菌药物	MIC50	MIC90	MIC范围		R(%)	MIC50	MIC90	MIC范围		R(%)
克林霉素	0.25	8.00	0.125	~8	33.3	0.25	8.00	0.125	~8	33.3
红霉素	0.50	8.00	0.125	~8	48.0	0.50	8.00	0.25	~8	49.7
左氧氟沙星	1.00	8.00	0.5	~8	20.0	1.00	8.00	1	~16	28.4
利奈唑胺	2.00	2.00	1	~16	1.3	2.00	2.00	1	~8	1.6
呋喃妥因	32.00	32.00	16	~64	0.0	32.00	32.00	32	~128	0.5
青霉素G	0.032	0.032	0.015	~16	2.7	0.032	0.032	0.015	~16	1.6
四环素	16.00	16.00	1	~32	92.0	16.00	16.00	1	~16	90.2
万古霉素	0.50	0.50	0.5	~32	0.0	0.50	0.50	0.5	~32	0.0
抗菌药物	2011年(238株)					2012年(264株)
抗菌药物	MIC50	MIC90	MIC范围		R(%)	MIC50	MIC90	MIC范围		R(%)
克林霉素	0.25	8.00	0.25	~8	33.2	0.25	8.00	0.125	~8	33.3
红霉素	0.50	8.00	0.25	~8	49.6	1.00	8.00	0.125	~16	56.5
左氧氟沙星	1.00	8.00	1	~8	30.3	1.00	8.00	1	~8	30.7
利奈唑胺	2.00	2.00	2	~2	0.0	2.00	2.00	0.5	~2	0.0
呋喃妥因	32.00	32.00	32	~128	0.4	32.00	64.00	16	~256	7.2
青霉素G	0.032	0.032	0.03	~16	0.4	0.032	0.032	0.03	~8	0.4
四环素	16.00	16.00	1	~16	90.3	16.00	16.00	1	~16	90.5
万古霉素	0.50	0.50	0.5	~2	0.0	0.50	0.50	0.5	~2	0.0

[1]	WANG Chao, ZHAO Yu. Research progress on formation mechanism and eradication strategy of bacterial persisters [J]. Laboratory Medicine, 2023, 38(8): 790-795.
[2]	ZHU Yurong, ZHANG Dan, HE Yaxing, LI Jingjing, HUANG Jing, LI Ting, LIU Peng, LIU Ronghua. Classification and epidemiology characteristics of Klebsiella pneumoniae isolated from clinic [J]. Laboratory Medicine, 2023, 38(5): 435-440.
[3]	FANG Yongmei, ZHANG Yan, XU Xueying, ZHONG Feng. Correlation of Staphylococcus aureus drug resistance with drug resistance genes and virulence genes [J]. Laboratory Medicine, 2023, 38(4): 357-361.
[4]	WANG Jiawei, ZHU Weinan, CHEN Yingying, JI Ping, WANG Ying. Clinical characteristics，molecular typing and drug resistance genes of carbapenem-resistant Klebsiella pneumoniae isolated from blood culturing [J]. Laboratory Medicine, 2023, 38(4): 362-367.
[5]	REN Yanfei, ZHANG Min, YANG Tao, LI Rongkai, LIANG Xin. Analysis of pathogenic epidemiology of patients with lower respiratory tract infection in respiratory intensive care unit [J]. Laboratory Medicine, 2023, 38(2): 157-162.
[6]	DENG Chen, DAI Jiaze, QIU Lihong, SHEN Weiting, CAI Mufa, LUO Wenying. Molecular epidemic characteristics of hypervirulent Klebsiella pneumoniae in Zhanjiang [J]. Laboratory Medicine, 2023, 38(11): 1026-1031.
[7]	RU Haohao, CHEN Lianyong, YANG Xing, CHEN Tao, YAN Shuangqun, XU Lin. Analysis of rifampicin resistance in Mycobacterium tuberculosis determined by Xpert MTB/RIF and phenotypic drug susceptibility test [J]. Laboratory Medicine, 2023, 38(11): 1032-1035.
[8]	WANG Su, DING Li, JIANG Wenrong, MIAO Yingxin, ZHANG Yanmei, ZHAO Hu. Research progress on drug resistance and treatment strategies of hypervirulent Klebsiella pneumoniae [J]. Laboratory Medicine, 2023, 38(1): 81-86.
[9]	HAO Jiahui, YANG Zehua. Research progress of bacterial integron determination methods [J]. Laboratory Medicine, 2022, 37(9): 887-891.
[10]	LIU Jingxian, CHEN Xingyue, ZHAO Jing, LIU Ying. Clinical characteristics and molecular epidemiology of Streptococcus agalactiae infection in non-pregnant adults [J]. Laboratory Medicine, 2022, 37(8): 793-797.
[11]	LI Hua, WANG Weiliang, XIE Bei, YANG Yu, MENG Fanrong, WANG Nan, LIU Zhihui, ZHANG Yanbin. Feasibility of the determination of heterogeneous drug resistance to rifampicin in Mycobacterium tuberculosis by flow cytometry [J]. Laboratory Medicine, 2022, 37(6): 577-582.
[12]	SUN Xiaodan, LIU Yiwen, HE Yiqing, DU Yan, ZHANG Guoliang, GAO Feng, YANG Cuixia. Research progress on the role of estrogen receptor in osteosarcoma [J]. Laboratory Medicine, 2022, 37(4): 313-318.
[13]	WANG Jianying, WANG Shanshan, ZHU Jun, HUANG Xiaochun, WAN Yuxiang, LIU Yun. Distribution and drug resistance of respiratory infection pathogens in patients with lung cancer after chemotherapy [J]. Laboratory Medicine, 2022, 37(4): 356-359.
[14]	SUN Ying, LI Yi, YAN Wenjuan, JING Nan, MA Bing. Analysis of drug resistance of rare CRE and clinical application of carbapenem screening test in Henan [J]. Laboratory Medicine, 2022, 37(2): 146-149.
[15]	WANG Lixin, SU Yunfu, WANG Yi. Research progress on the drug resistance mechanism of clinical pathogens to fosfomycin [J]. Laboratory Medicine, 2022, 37(10): 993-997.